About Chemomab Therapeutics DRC
Chemomab Therapeutics (NASDAQ:CMMB) is a biotech company focusing on the discovery and development of innovative therapies for fibrosis-related diseases and inflammation. With a deep understanding of the molecular pathways that drive these conditions, Chemomab is committed to advancing a pipeline of novel drug candidates designed to address unmet medical needs. The company's lead project involves a monoclonal antibody targeting a key regulator of fibrosis and inflammation, showing promise in various clinical trials. Chemomab aims to transform the treatment landscape for patients suffering from debilitating diseases where current therapies are inadequate or non-existent, demonstrating a strong commitment to improving patient outcomes through scientific excellence and targeted drug development.
Snapshot
Operations
Products and/or services of Chemomab Therapeutics DRC
- Development of CM-101, a first-in-class monoclonal antibody targeting CCL24 for fibrotic diseases.
- Clinical trials for treating Primary Sclerosing Cholangitis, a rare liver disease.
- Studies on CM-101's effectiveness for Non-Alcoholic Steatohepatitis, a liver condition.
- Research into CM-101's potential for treating systemic sclerosis.
- Exploration of CM-101's application in idiopathic pulmonary fibrosis.
- Investigation into CM-101's effects on kidney fibrosis.
Chemomab Therapeutics DRC executive team
- Dr. Adi Mor George Ph.D.Co-Founder, Chief Scientific Officer, CEO & Executive Director
- Ms. Sigal Fattal CPA, M.B.A.Chief Financial Officer
- Barbara LindheimConsulting Vice President of Investor & Public Relations, Strategic Communications
- Dr. David M. Weiner M.B.A., M.D.Interim Chief Medical Officer
- Mr. Jack LawlerChief Development Officer